Overview of Lomet

This section provides a factual identity of Lomet, covering its composition, classification, and general purpose as an oral medication for diabetes management.

Property	Description
Active ingredient	Glimepiride
Form	Oral Tablet
Pharmacological class	Sulfonylurea, Antidiabetic Agent
Common use	Management of high blood sugar in Type 2 Diabetes Mellitus
Origin	Synthetic Organic Compound

What Type of Medicine is Lomet (Glimepiride)?

Lomet is a prescription-only oral antidiabetic agent used for the management of high blood sugar levels in adults with type 2 diabetes mellitus. The medicine's active ingredient is glimepiride, which belongs to the well-established sulfonylurea pharmacological class. It is specifically categorized as a synthetic second-generation sulfonylurea, a classification that is clinically recognized for its efficacy in improving glycemic control. This information confirms that glimepiride is a primary tool used to help patients keep their blood sugar levels within a healthy range. Glimepiride is also distinguished within its class for its rapid onset of action and relatively long duration, which often permits a single daily dose, streamlining therapy for adults managing this condition.

Composition and General Purpose of Lomet

Lomet is a single-component product presented as an oral dosage form, typically a tablet, which is taken by mouth to help regulate blood glucose. The primary composition includes only the therapeutic agent, glimepiride, alongside necessary solid pharmaceutical excipients that form the tablet matrix. Its general purpose is to support the body in overcoming the inadequate insulin response characteristic of type 2 diabetes mellitus, thus working to lower high blood sugar. The drug's profile identifies its role as a key hypoglycemic agent used to stimulate insulin secretion. This confirms that Lomet works to activate the body's own system to manage sugar effectively. Glimepiride is often selected when patients require robust stimulation of insulin to maintain blood sugar targets, representing a common, second-line treatment option when initial management is insufficient.

How Glimepiride Affects Blood Sugar Levels

Glimepiride acts as an insulin secretagogue, meaning its fundamental physiological action is to stimulate the pancreatic beta cells to increase the release of insulin. This essential action provides the body with the extra insulin needed to transfer sugar (glucose) from the bloodstream into the body's cells. This high-level function is pharmacologically confirmed to ensure that the body’s system is encouraged to produce and utilize more insulin to manage high blood sugar levels, confirming its primary function in maintaining glycemic control for adults with this condition.

What side effects are possible with Lomet?

Possible Side Effects and Safety Information

The safety profile of Lomet (Metformin) is documented through regulatory sources, categorizing adverse reactions by frequency and potential severity.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their documented occurrence in clinical trials:

Very Common (occurring in more than 1 in 10 patients): Gastrointestinal disorders, including diarrhea, nausea, vomiting, abdominal pain, and loss of appetite. These are most frequent at the start of therapy.
Common (occurring in 1 in 100 to 1 in 10 patients): Taste disturbance (metallic taste).
Very Rare (occurring in less than 1 in 10,000 patients): Lactic acidosis, liver function test abnormalities or hepatitis (resolving upon discontinuation), and certain skin reactions (erythema, pruritus, urticaria).

Serious Adverse Reactions and Restrictions

Lactic Acidosis is a rare but serious metabolic complication formally documented in regulatory safety information, often associated with drug accumulation. The risk is significantly increased by underlying conditions such as severe kidney impairment, conditions that cause tissue hypoxia (like heart failure or severe infection), or excessive alcohol intake.

Contraindications (Situations where use is not permitted): Lomet is formally restricted for use in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m^2), acute metabolic acidosis, severe dehydration, or acute conditions that may impair kidney function. The use of iodinated contrast materials during imaging procedures requires temporary discontinuation of the medicine in certain at-risk patients.

Population Safety Notes: Renal function must be assessed prior to and regularly during therapy, particularly in geriatric patients who may have reduced kidney function. Long-term use of the medicine has been associated with a potential decrease in serum Vitamin B12 levels, which may lead to megaloblastic anemia.

Overdose and Emergency Response

An overdose of Lomet (Glimepiride) is officially documented to cause severe and prolonged hypoglycemia (dangerously low blood sugar), which can lead to life-threatening complications.

Documented Overdose Manifestations

System	Official Regulatory-Listed Signs/Symptoms
Neurological	Confusion, headache, tremor, somnolence, seizures, speech disorders, and eventual loss of consciousness (coma) [Source: FDA/EMA Labeling].
Autonomic/Systemic	Sweating, anxiety, clammy skin, nausea, rapid heartbeat (tachycardia), and vomiting [Source: FDA/EMA Labeling].

Required Emergency Actions

Immediate medical attention is mandatory for any suspected overdose due to the risk of severe and recurrent hypoglycemia. Even if initial symptoms are corrected by consuming sugar, this does not negate the need for professional medical assessment. Individuals must be referred to a medical facility for assessment.

When to Seek Urgent Help: You must call emergency services immediately if the person has collapsed, is experiencing seizures, or cannot be awakened [Source: MedlinePlus].

Supportive Care and Monitoring

Overdose management, as defined in regulatory guidelines, involves intravenous glucose to maintain normal blood sugar (euglycemia). Due to the prolonged effect of Glimepiride, patients require frequent blood glucose monitoring and prolonged observation periods (often 12–24 hours) in a healthcare setting to prevent the documented risk of recurrent hypoglycemia. Infants and children are noted as a population at higher risk for serious, long-term complications from uncorrected low blood sugar.

Therapeutic Uses of Lomet

What Lomet Treats: Main Uses and Benefits

Lomet is a medicine commonly used in contexts involving certain distressing symptoms. It is applied across domains where additional symptomatic support is needed, primarily used in situations involving certain distressing symptoms, thus supporting general well-being during symptomatic phases.

Lomet is commonly applied in addressing conditions presenting with acute episodes, such as duodenal and gastric ulcers, symptomatic Gastro-esophageal Reflux Disease (GERD), and erosive esophagitis. The medicine is also relevant for easing symptoms linked to organ-specific functional stress, such as pathological hypersecretory conditions, like Zollinger-Ellison syndrome, and may assist with symptoms that become more disruptive during flare-ups in conditions involving recurrent or episodic manifestations. Lomet supports the patient during difficult episodes by easing distress associated with heartburn, acid regurgitation, and discomfort.

It provides supportive relief when symptoms interfere with routine activities, supporting patients during episodes of heightened discomfort, which may assist with maintaining functional stability. The medicine contributes to easing the overall symptom load during symptomatic periods, which is often used during phases when symptoms become more noticeable.

Quick Fact: Relief for Heartburn and Acid Regurgitation

Regulatory References

European Medicines Agency therapeutic document

Eligibility and Restrictions for Use

Lomet (glimepiride) is officially indicated for use in adults with Type 2 Diabetes Mellitus. Regulatory documents define specific exclusion criteria and restrictions that govern its use among different populations.

Absolute Contraindications

Lomet is contraindicated and must not be used by patients with Type 1 Diabetes Mellitus or diabetic ketoacidosis (DKA). Use is also strictly prohibited in individuals with a known allergy or hypersensitivity to glimepiride or any other sulfonamide derivatives. Furthermore, official regulatory documents state that the medicine is contraindicated in patients with severe hepatic or severe renal function disorders, necessitating a switch to insulin therapy.

Age-Related and Special Population Restrictions

Lomet is not recommended for the pediatric population (under 18 years) due to insufficient data regarding safety and efficacy. Use is advised against during both pregnancy and breastfeeding, as patients must be switched to insulin therapy in these physiological states. Elderly patients and those with non-severe renal or hepatic impairment must use Lomet only with special caution, as these groups are at an increased risk of hypoglycemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interaction patterns for Lomet (Glimepiride) as found in government regulatory sources, focusing on pharmacokinetic (PK) and pharmacodynamic (PD) outcomes.

Official Interaction Statements

Metabolic and Exposure Interactions

Glimepiride is primarily metabolized by the Cytochrome P450 2C9 (CYP2C9) enzyme. Co-administration with CYP2C9 inhibitors, such as Fluconazole, may increase Glimepiride plasma concentration. Conversely, CYP2C9 inducers, such as Rifampin, may decrease Glimepiride exposure, potentially reducing its effectiveness.

Pharmacodynamic and Additive Effects

Use with other Antidiabetic Agents (e.g., Insulin or Metformin) is documented to result in an additive glucose-lowering effect, which increases the risk of low blood sugar. This additive PD effect is a key constraint in combination therapy.

Interactions Affecting Absorption

The bile acid sequestrant Colesevelam may reduce the gastrointestinal absorption of Glimepiride. To mitigate this PK interference, the regulatory label requires Glimepiride to be administered at least 4 hours prior to Colesevelam administration.

Substance-Specific Restrictions

The concomitant use of oral Miconazole may lead to a risk of severe hypoglycemia.

Population-Specific Considerations

Patients with renal or hepatic impairment are officially noted as being susceptible to the hypoglycemic action of Glimepiride due to reduced drug clearance and potential for higher serum concentrations.

Mechanism of Action

How Lomet (Glimepiride) Works

Lomet's action is governed by two complementary mechanistic domains that target the body's sugar-regulating pathways.

Stimulating Insulin Release via mathbfKmathbfATP Channel Blockade

This domain describes the primary action on the pancreas, where the active ingredient Glimepiride binds to the Sulfonylurea Receptor 1 (SUR1) subunit of the ATP-sensitive potassium channel (K ATP channel) on the beta-cell membrane. The resulting channel closure initiates a cellular cascade—membrane depolarization followed by calcium influx—that triggers the release of pre-formed insulin into the bloodstream. This secretagogue effect generates the hormonal signal that leads to increased glucose uptake and utilization in target tissues.

Enhancing Peripheral Tissue Sensitivity

Glimepiride also influences pathways in peripheral tissues like muscle and fat via its extrapancreatic mechanism. This action enhances the responsiveness of these cells to insulin, promoting the translocation of Glucose Transporter Type 4 (GLUT4) to the cell surface. The resulting physiological effect is a greater uptake and utilization of glucose from the circulation, contributing to the overall systemic decrease in circulating glucose concentration.

Constraints on Mechanistic Efficacy

Glimepiride’s mechanism is strictly dependent on the presence of functioning, residual pancreatic beta-cells for its action to occur. The mechanism demonstrates a lower binding affinity for K ATP channels in the heart compared to those in the pancreas. This difference in binding affinity influences the effect of the molecule on ischemic preconditioning pathways.

Dosage and Administration Information

How to Use Lomet: Official Administration Guidelines

Lomet (Glimepiride) is an oral medication prescribed for the long-term management of high blood sugar in adults with Type 2 Diabetes Mellitus. The administration protocol is standardized to ensure effective use.

Standard Dosing and Frequency

Glimepiride is formulated as an oral tablet in strengths including 1 mg, 2 mg, and 4 mg. The medicine must be taken once daily.

Initial Dose: Therapy typically begins with 1 mg or 2 mg once daily.
Maintenance Range: The usual maintenance dose is 1 mg to 4 mg once daily.
Maximum Dose: The total daily dose should not exceed 8 mg.

Administration Conditions

Condition	Instruction
Timing	Administer with breakfast or the first main meal of the day.
Titration	Dose adjustments are made in increments of 1 mg or 2 mg at intervals of 1 to 2 weeks based on response.
Missed Dose	If a dose is missed, patients should not double the dose at the next scheduled time.

Population-Specific Use

Older adults and patients with renal impairment are generally started on the lowest dose of 1 mg once daily, and the dose is increased cautiously. The tablet should be swallowed whole with liquid and should not be crushed or chewed.

Recent Clinical Evidence

Research evidence / Overview of studies for Lomet

Evidence for use in Type 2 Diabetes Mellitus as Monotherapy

Research on Lomet (Glimepiride) began with short-term randomized controlled trials (RCTs). These studies were used to evaluate Lomet when prescribed alone, comparing it to a placebo or to lifestyle changes. The researchers primarily focused on outcomes related to functional imbalance, specifically monitoring changes in key blood sugar markers like Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG) in adults newly diagnosed with or previously untreated for Type 2 Diabetes.

The findings from these initial trials describe patterns related to the measurements of blood sugar biomarkers. Studies reported how these key markers evolved in the observed populations during the study period. Despite these findings, there are known research limitations. The initial follow-up durations were typically short-term, meaning the evidence provides limited insight into the long-term sustained observation of blood sugar measurements over many years. Also, these results apply only to the populations studied.

Evidence for use in Combination Therapy

Research also examined Lomet's role when it is added to other existing medications, such as Metformin or insulin, for people whose blood sugar was inadequately controlled by base therapy. These medium- to long-term RCTs explored outcomes capturing phases of insufficient glucose control with the base therapy alone. Research exploring short-term symptom changes described measured changes in HbA1c levels in addition to base therapy.

Studies Comparing Lomet to Other Antidiabetic Medicines

A significant part of the research involves comparing Lomet to newer and established drug classes, including dedicated long-term cardiovascular outcome trials (CVOTs). These large-scale studies were evaluated in adults, often including those who already faced a higher risk for heart-related issues. They monitored serious outcomes, such as the occurrence of Major Adverse Cardiovascular Events (MACE) over several years. The evidence derived from these settings describes patterns related to the measurement of cardiovascular event rates in comparative treatment settings.

What Research Gaps and Uncertainties Remain

The research on Lomet contributes to the broader evidence landscape, but like all medicines, it has known gaps and limitations. One key area is that comparative evidence is lacking for Lomet against every available antidiabetic treatment, which necessitates relying on synthesized data (meta-analyses) for some comparisons. Furthermore, some findings regarding the differences between Lomet and other agents within its own class were observed in studies that were not large, head-to-head RCTs, meaning the certainty remains low in some areas.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Lomet (FAQ)

Q: How quickly does Lomet typically start to work after the first dose?

Regulatory documents describe that the maximum blood sugar-lowering effect is typically measured around 2 to 3 hours following a single oral dose.

Q: What are the most common side effects people report when starting Lomet?

Official data indicates that gastrointestinal side effects, such as nausea and diarrhea, are very common and are noted to be most frequent at the initiation of therapy. Other common reactions reported in clinical studies include low blood sugar (hypoglycemia), headache, and dizziness.

--UN

Q: Can Lomet be taken by people who have liver or kidney issues?

Regulatory documents state that this medicine is not permitted for use in patients with severe kidney impairment. For individuals with mild to moderate kidney impairment or liver issues, official instructions recommend starting at the lowest dose and adjusting cautiously.

Q: What are the less common, but more serious, safety concerns associated with Lomet?

Official sources describe serious, though less common, safety concerns. These include the risk of severe hypoglycemia (very low blood sugar), Lactic Acidosis (a rare but severe metabolic complication), and severe allergic reactions such as anaphylaxis, angioedema, and severe skin reactions.

Q: How will I know for sure if Lomet is actually working for me?

The effectiveness of Lomet is generally measured by tracking changes in specific blood sugar markers. These key markers include Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG) levels, as documented in clinical studies.

Q: What is the difference between the brand name Lomet and its active ingredient name?

Lomet is the brand name of the medicine. Its active ingredient—the chemical compound that makes the medicine work—is officially called Glimepiride.

Q: Does Lomet cause weight gain or weight loss?

Official safety data indicates that weight gain has been reported as a potential side effect associated with the use of Lomet. However, it is not listed among the most common adverse reactions.

Q: Is Lomet considered a safe medication for people with heart conditions?

The class of medicines Lomet belongs to (sulfonylureas) has been associated with a potential increased risk of cardiovascular mortality. Official clinical studies have not established conclusive evidence that Lomet reduces risks related to major heart and blood vessel complications (macrovascular risk).

Q: How common is it for Lomet to cause gastrointestinal side effects like nausea or diarrhea?

Gastrointestinal side effects, which include nausea and diarrhea, are documented as very common in regulatory information. This means they were reported to occur in more than 1 in 10 patients in clinical trials.

Q: Will Lomet definitely cure my condition, or does it only manage symptoms?

According to the FDA label, Lomet is indicated as an adjunct to diet and exercise to improve glycemic control. It is officially indicated for the management of high blood sugar, and not as a curative treatment.

Q: Is it necessary to take Lomet at the exact same time every day?

Official instructions state the medicine must be taken once daily with breakfast or the first main meal of the day. This consistent daily schedule around this mealtime is based on the recommendation for consistent dosing around the mealtime.

Q: Is it common to feel worse or have unusual symptoms when first starting Lomet?

Gastrointestinal side effects, such as diarrhea and nausea, are listed as very common and are noted in official documents to be most frequent at the start of therapy. This adjustment period can be expected by some users.

Q: Is there a generic version of Lomet available?

Yes, regulatory documents confirm that the active ingredient, Glimepiride, is widely available as a generic tablet product.

Q: Does the time of day I take Lomet (morning vs. evening) make a difference?

Official instructions specify that the medicine should be administered with breakfast or the first main meal of the day.

Q: Can pregnant or breastfeeding people use Lomet?

Official regulatory warnings state that the use of Lomet during pregnancy is not recommended. Similarly, breastfeeding is also not recommended while a person is using the medicine.

Q: Will Lomet change the results of any routine blood tests?

Long-term use of Lomet has been associated in official warnings with a potential decrease in serum Vitamin B12 levels. This decrease, which is measured through blood tests, can potentially lead to a form of anemia.

Q: How long does the main ingredient from Lomet stay in the body after stopping treatment?

The elimination half-life of the active ingredient, Glimepiride, is typically reported to be approximately 4 to 8.7 hours after the last dose.

Q: Does Lomet have a known potential for dependence or addiction?

Lomet is not classified as a controlled substance by regulatory bodies. The official warnings and precautions do not include a discussion of dependence or abuse risk.

Q: Are there any genetic factors that might affect how a person responds to Lomet?

Yes, official warnings indicate that Lomet can cause hemolytic anemia in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, which is a hereditary genetic condition.

Q: Does taking Lomet make you more sensitive to sun exposure?

Regulatory information includes reports of photosensitivity (increased sensitivity to the sun) as a possible adverse reaction. It is a less common reaction, but it is documented.

Q: Is there a maximum time frame that a person should remain on Lomet?

Lomet is indicated in official documents for the long-term management of high blood sugar in adults with Type 2 Diabetes Mellitus.

Q: Can Lomet cause fatigue or make me feel tired?

Clinical trial data lists weakness and dizziness as common side effects. Furthermore, fatigue is a known symptom associated with hypoglycemia (low blood sugar), which is a very common side effect of the medicine.

Q: Is it possible to be allergic to Lomet, and what are the symptoms?

Yes, Lomet is contraindicated (not permitted) for use in people with a history of hypersensitivity (allergic) reaction to the medicine itself or to other sulfonamide drugs. Severe allergic symptoms can include swelling (angioedema) and anaphylaxis.

Q: Does Lomet come in different forms (e.g., tablet, liquid, extended-release)?

The medicine is formulated as an oral tablet and is available in multiple strengths, including 1 mg, 2 mg, and 4 mg.

Q: Does taking Lomet require any special monitoring or regular check-ups?

Official information requires that kidney (renal) function must be assessed prior to and regularly during therapy. For long-term use, monitoring for potential decreases in serum Vitamin B12 levels is also necessary.

Q: Are there any specific foods or drinks I should avoid while taking Lomet?

Regulatory warnings specifically state that hypoglycemia (low blood sugar) is more likely to occur when caloric intake is deficient or when alcohol is ingested.

Q: Can Lomet affect my ability to drive or operate machinery?

Official warnings indicate that the ability to concentrate and react may be impaired as a result of hypoglycemia (low blood sugar). This may present a risk in situations such as driving or operating machinery.

Q: Is it possible for Lomet to cause emotional or mood changes?

Symptoms of hypoglycemia (low blood sugar), which is a common side effect, can include various emotional and behavioral changes. These include anxiety, confusion, irritability, and difficulty in thinking.

Q: What is the current status of research on Lomet's long-term effects?

Official documents note that long-term clinical studies have not established conclusive evidence regarding the medicine's effect on macrovascular risk reduction (serious heart and blood vessel problems). It is also noted that long-term use has been associated with a potential decrease in serum Vitamin B12 levels.

Q: Is Lomet commonly used in combination with other treatments for my condition?

Yes, Lomet is indicated for use alone (monotherapy) or in combination with other anti-diabetic agents, such as insulin or metformin, if the response to Lomet alone is inadequate.

Q: What kind of patients is Lomet typically recommended for?

Lomet is officially indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes Mellitus.

How should Lomet be stored and disposed of?

How to Store and Dispose of Lomet?

Storage Requirements

Lomet tablets must be stored under controlled conditions to ensure stability as defined by regulatory labeling.

Storage Constraint	Requirement per Official Labeling
Temperature	Store at or below the maximum labeled temperature (e.g., 25 C or 30 C), and keep from freezing.
Environmental Protection	Must be protected from light and moisture and kept in the original container.
Child Safety	Mandatory to be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Lomet must be disposed of according to local guidelines, which typically involve official drug take-back programs or consultation with a pharmacist. Regulatory instructions state that the medicine should not be discarded into drains or released into the environment. Patients are directed to ask a doctor or pharmacist for the proper disposal method for any unused product.

Lomet